UPClytics
Alle Fälle anzeigen

ORD 55063/2024

·EP3977921: ANALYTE SENSOR AND APPARATUS FOR INSERTION OF THE SENSOR

Verfahrensdetails
Status
Verfahrensart
Verfahrensantrag
Kategorie
Verfahrensführungsanordnungen
Parteien
Kläger
Vertreter: Wim Maas
Beklagte
Vertreter: Tjibbe Douma
Division
Nordic-Baltic RD
Richter
Technology
Biotechnology
Sprache
Erste Entscheidung
7. Okt. 2024
Entscheidungen
  • 2024-10-07
    Generic Order

    Nordic-Baltic Regional Division (judge-rapporteur Kai Härmand) preliminary/case management order in Abbott Diabetes Care Inc.'s infringement action against Dexcom Inc. and Dexcom International Limited concerning EP 3 977 921 (a continuous glucose monitoring patent). The order addresses multiple pending applications including Abbott's R. 190 application to communicate information (partially dismissed following Paris LD precedent), Abbott's R. 191 application (found admissible but not justified), Abbott's application to change the statement of claim, Dexcom's request for security for legal costs, and sets procedural deadlines and oral hearing preparation steps.

    Rechtsfragen:Application to communicate information (R. 191 RoP / Art. 67 UPCA) – admissible but not justifiedR. 190 RoP evidence orderAmendment of statement of claimSecurity for legal costsPending EPO opposition proceedingsProcedural deadlines and oral hearing preparation
Dokumente
  • 8AB7F004808A045446F38FDD51B1F8DF_en.pdf2024-10-07EN